Objective: Prebiotics and phytoestrogens have sparked great interest because evidence indicates that the consumption of these dietary constituents leads to lower cholesterol levels and inhibition of postmenopausal bone loss. The aim of this study was to determine the effect of both a prebiotic (Synergy) and a phytoestrogen (genistein) on bone and blood lipid levels in an animal model of postmenopausal women.
P ostmenopausal women experience declines in bone and cardiovascular health primarily because of age-related changes in metabolism and estrogen deficiency. Prebiotics and phytoestrogens have sparked great interest because evidence indicates that the consumption of these dietary constituents leads to lower cholesterol levels and inhibition of postmenopausal bone loss. Prebiotics, including inulin, oligosaccharides, and short-chain fructooligosaccharides (sc-FOS), have been shown to enhance mineral absorption and increase bone mineral density (BMD). 1, 2 Mixtures of inulin and oligosaccharides have been reported to impart more bone health benefits than other prebiotics. 3 Our previous research demonstrated that the chronic feeding of Synergy (a 50%:50% mix of inulin and sc-FOS) resulted in an increased calcium absorption and BMD and in the suppression of bone resorption in ovariectomized rats. 4 Prebiotics exert their effects by augmenting anaerobic fermentation in the large intestine, resulting in the formation of short-chain fatty acids (SCFAs). 5 These fermentation products (and other changes caused by polysaccharides) may alter the conditions of the large intestine by changing transit time, decreasing pH level, and lowering the conversion of primary to secondary bile acids. 5, 6 It is postulated that prebiotics create optimal conditions for calcium absorption by lowering pH level, inhibiting the binding of calcium to bile acids, and increasing absorptive surface area in the large intestine. 6 Actions of prebiotics in the intestine have also been associated with other health benefits including positive effects on lipid metabolism 7 and lower cardiovascular disease risk. 8 Phytoestrogens also provide bone and heart benefits. Phytoestrogens, particularly soy isoflavones, have received much attention as an alternative therapy to estrogen for preventing age-related bone loss. Estrogen deficiency, which leads to reduced calcium retention, is the underlying etiology of osteoporosis in postmenopausal women. Earlier work in our laboratory showed that soy supplements containing genisteinlike soy isoflavones were more effective than other commercial soy supplements in suppressing bone resorption in postmenopausal women. 9 Other clinical studies have also shown that genistein supplementation helps mediate postmenopausal bone loss. 10, 11 The primary mode of action for genistein is thought to be through binding to estrogen receptor-A, which could repair the imbalance in bone remodeling (bone resorption 9 bone formation) that occurs with advancing age and hormone deficiency by suppressing osteoclastogenesis. Genistein raises osteoprotegerin levels. 12, 13 Osteoprotegerin plays a crucial role in blocking osteoclastogenesis by serving as a decoy receptor for the receptor activator of nuclear factor J ligand. 14 However, other studies have shown that genistein can also influence bone remodeling by promoting bone formation and by exerting actions through estrogen receptor->, 15<17 suggesting that further research is needed to clearly distinguish the effect of genistein on bone remodeling. Dietary phytoestrogens have also been shown to reduce cardiovascular disease risk by lowering cholesterol levels. 18 It is speculated that phytoestrogens exert heart health benefits by altering lipid metabolism. An in vitro study found that genistein lowers the oxidative susceptibility of low-density lipoprotein (LDL). 19 Supplementing with a combination of phytoestrogens and prebiotics, sc-FOS, and soy isoflavones resulted in greater BMD 20<22 in several rodent studies. Here, we report a study with both a prebiotic (Synergy) and phytoestrogen (genistein), which have independently shown bone-sparing effects on ovariectomized (OVX) animals in an animal model of postmenopausal women, to study the mechanisms involved in bone and blood lipid levels in response to ovariectomy. The aims of this study were to determine (1) the adaptation of calcium metabolism with prebiotic and genistein consumption and (2) the chronic effects of Synergy and genistein on bone and heart health. We hypothesized that (1) Synergy and genistein consumption would improve blood lipid levels and inhibit ovariectomy-induced bone loss by affecting calcium absorption and bone remodeling, respectively, and (2) chronic consumption of both would have a greater effect on the bone than would the consumption of either Synergy or genistein alone.
METHODS

Animals
Ninety-six virgin female Sprague-Dawley rats, of which 80 were OVX and 16 were sham operated at 3 months old, were purchased from Harlan (Indianapolis, IN). The animals were fed a maintenance rat chow diet for 2 months to stabilize after ovariectomy before shipment at 5 months of age. The rats were housed in individual cages in a temperature-and humiditycontrolled room with the lights on a 12-hour/12-hour on-off cycle. An AIN-93M 23 diet and distilled water were provided ad libitum for an acclimation period of 2 days. All procedures were approved by and performed in compliance with the rules of Purdue University's Animal Care and Use Committee.
Diet
Genistein (Indofine Chemical Company, Hillsborough, NJ) and Synergy (Orafti, Tienen, Belgium) were mixed thoroughly with AIN-93M base diet 23 ingredients (Research Diets, New Brunswick, NJ) for the following dietary treatments: 200 mg genistein/kg diet, 50 g Synergy/kg diet, and 200 mg genistein/kg diet + 50 g Synergy/kg diet.
Study design
All OVX rats were weighed and assigned to one of the following treatments to ensure similar mean body weight across OVX rat groups (n = 16 per group): control group (OVX-CON), estradiol group (OVX-E 2 ), genistein group (OVX-GEN), Synergy group (OVX-SYN), and combined genistein and Synergy group (OVX-GEN + SYN). The sham, OVX-CON, and OVX-E 2 groups were fed the AIN-93M diet, whereas the OVX-GEN, OVX-SYN, and OVX-GEN + SYN groups were fed the AIN-93M diets with an additional 200 mg genistein/kg, 50 g Synergy/kg, and 200 mg genistein and 50 g Synergy/kg, respectively. OVX-E 2 rats also received biweekly SC injections of 25 Kg/kg of body weight E 2 (Sigma-Aldrich, St. Louis, MO) via a carrier solution of 4% dimethyl sulfoxide in saline. After 4 weeks of dietary treatment (equivalent to one bone remodeling cycle), the rats were fasted for 8 hours before they were killed. Animals were euthanized using excess carbon dioxide. Blood was drawn via the abdominal aorta, and plasma was stored at j80-C for biochemical analysis. Cecal contents were removed and rapidly frozen in liquid nitrogen before being stored at j80-C for subsequent SCFA analysis. The cecum was flushed twice with 12 mL of ice-cold saline, and the cecal wall weight was recorded. The right femurs and tibiae were wrapped in saline-soaked gauze and stored at j20-C for evaluation of bone mechanical properties. The left femurs and tibiae were collected and placed in 70% ethanol and stored at 4-C for scanning by peripheral quantitative computed tomography (pQCT).
Biochemical markers
Plasma genistein concentrations were quantified using a highly sensitive and specific electrospray ionization liquid chromatographyYmultiple-reaction ion monitoring mass spectrometry method, as described previously. 24 Genistein was detected using the transition of its m/z 269 molecular ion to its m/z 133 fragment ion.
Plasma total, high-density lipoprotein (HDL), and LDL cholesterol levels were determined using commercial assays and the COBAS Integra 400 Analyzer (Roche Diagnostics Inc., Summerville, NJ).
Bone density, size, and mechanical properties
The right femurs and tibiae were measured for length and width at the midshaft using an ABS digimatic solar caliper (Tri-State Instrument Service, Fort Wayne, TX). Bone density was measured by underwater weighing using a density determination kit and Mettler Toledo analytical balance (Mettler Toledo Inc., Columbus, OH). Bone strength was assessed using a three-point bending test on a materials testing machine (Alliance RT/5; MTS Systems, Eden Prairie, MN), as described previously. 25 
Bone calcium content
After mechanical testing, the right femurs and tibiae were dissolved in concentrated nitric acid overnight, diluted with ultrapure water, and analyzed for total calcium content using atomic absorption spectrometry (PE S100; Perkin Elmer Inc., Boston, MA).
Calcium balance and kinetics
An early metabolic balance (3 d after the start of treatment) was conducted to determine acute effects on calcium absorption and metabolism. Urine and feces were collected every 24 hours for 96 hours and analyzed for calcium. To assess the chronic effects of dietary genistein and Synergy on calcium absorption and metabolism, calcium kinetics and a late metabolic balance were performed during the last week of the feeding study, as reported previously, 24 with the following modifications in blood collection time points: 0, 5, 15, 30, 60, 80, 130,180, 240, 480, 720, and 1,440 minutes. Blood samples were centrifuged, and serum was collected and stored at j80-C for 45 Ca analysis, as previously described by our group. 25 For the late metabolic balance, urine and feces were collected every 24 hours for 96 hours after the oral or IV dosing of 45 Ca. The radioactivity of 45 Ca was measured in urine and feces. The following parameters were calculated: Calcium absorption efficiency, bone calcium balance, bone formation rate, and bone resorption rate were determined using kinetic modeling. For kinetic modeling analysis, blood, urine, and fecal samples were fitted by the compartmental modeling approach, using the WinSAAM (Simulation Anal-ysis and Modeling) program, 26 available through the National Institutes of Health, with methods previously described. 25 pQCT measurements pQCT analysis was performed using the Stratec pQCT (model Research SA+ of Norland Stratec XCT; Stratec Electronics, Pforzheim, Germany). Three cross-sectional sites (1.0 mm thick) from the distal, midshaft, and proximal sites of bones, determined at 12%, 50%, and 88% of the length from the distal end, were scanned using a 0.46-mm collimation (4 Â 10 5 counts/s) and a 0.08-mm voxel size. Thresholds for the segmentation of the trabecular and cortical bones were set at 500 and 900 mg/cm 3 , respectively.
SCFA analysis
Approximately 0.3 g of cecal contents was ground into a powder using a mortar and pestle. The samples were prepared and analyzed in duplicate. All samples were stored on dry ice during use, and liquid nitrogen was added to the mortar and pestle to keep the samples frozen. An internal standard (500 KL of 3 mM 2-ethylbutyric acid in 70% ethanol) was added to each sample, and the samples were stored at 4-C overnight. The samples were centrifuged for 20 minutes at 11,500g at 4-C. A supernatant (100 KL) was removed from the sample and placed in an injection vial along with 100 KL of 70% ethanol. Immediately before injection, 10 KL of 10% (vol/vol) H 3 PO 4 was added to each injection vial. Samples were analyzed for acetate, propionate, butyrate, isobutyrate, valerate, and isovalerate concentrations using a Hewlett-Packard model 6890 gas chromatograph with a flame ionization detector (Agilent Technologies, Palo Alto, CA) equipped with a 30-m, 0.53-mm inside diameter capillary column coated with Hewlett-Packard free fatty acids phase, under conditions described previously. 27 
Statistical analysis
Data were analyzed using the Statistical Analysis System (SAS version 9.1; SAS Institute, Cary, NC). Plasma genistein concentrations were compared between the OVX-GEN and OVX-GEN + SYN groups using a two-tailed t test. Other treatment effects were determined using a one-way analysis of variance (ANOVA) and post hoc comparisons using Dunnett test (the sham and OVX-CON groups served as controls) after checking the normal distribution and constant variance assumptions of ANOVA. Because of group differences in body weight and calcium intake, an analysis of covariance was used, with body weight and/or calcium intake serving as a covariate when found to influence the model (P e 0.10). In the case of nonnormal distribution, data underwent log transformation before analysis by the one-way ANOVA and Dunnett test. Significance was accepted at P G 0.05.
RESULTS
Body and cecal wall weight
Total food intake and calcium intake were significantly lower in rats consuming genistein compared with all other groups. The sham group had significantly lower body weight than did any other OVX groups except OVX-E 2 (Fig. 1 ). Among the OVX groups, the OVX-GEN group had significantly lower body weight than OVX-CON ( Fig. 1 ).
Rats consuming Synergy (OVX-SYN and OVX-GEN + SYN) had a significantly higher cecal wall weight than did OVX-GEN and sham rats and higher than did the rats in the OVX-CON and OVX-E 2 groups (Fig. 2) .
Biochemical analysis
OVX-GEN rats had plasma total cholesterol concentrations significantly lower than did the rats in the OVX-CON (17%), OVX-E 2 (14%), and OVX-SYN (19%) groups and had plasma total cholesterol concentrations similar to those of the rats in the sham and OVX-GEN + SYN groups (Fig. 3 ). The sham rats had LDL cholesterol concentrations significantly lower than did the rats in the OVX-CON, OVX-SYN, and OVX-GEN + SYN groups and had similar LDL cholesterol concentrations to those of the OVX-E 2 and OVX-GEN rats. Sham and OVX-E 2 had similar HDL cholesterol concentrations, but HDL concentrations were lower than those observed in the OVX-CON, OVX-GEN, OVX-GEN + SYN, and OVX-SYN groups.
Plasma genistein concentrations were significantly higher in rats consuming Synergy with genistein compared with those consuming genistein alone (Fig. 4) .
Bone calcium content, size, and mechanical properties
The sham rats had higher femoral bone density than did those in the OVX-CON and OVX-E 2 groups (Table 1) and had significantly higher femoral breaking strength than did those rats in the OVX-CON, OVX-GEN, and OVX-GEN + SYN groups. The femoral breaking strength of the OVX-E 2 and OVX-SYN groups did not significantly differ from that of the sham rats. Sham, OVX-CON, and OVX-SYN rats had a similar femoral length that was significantly higher than that of the rats consuming genistein. There were no group differences in femoral width. Femoral calcium content was significantly higher in sham rats than in all OVX groups, except the OVX-E 2 group. Among the OVX groups, OVX-CON and OVX-E 2 groups had significantly higher femoral calcium content than did the OVX-GEN and OVX-GEN + SYN groups.
There were no differences in tibia bone density by underwater weighing, breaking strength, and width among the groups. Similar to that of the femur, tibia calcium content was significantly higher in sham rats than in all OVX groups. Among the OVX groups, the OVX-GEN + SYN rats had significantly higher tibia calcium content than did the OVX-GEN rats.
Calcium balance
In the early metabolic balance, calcium absorption efficiency in the OVX-GEN + SYN group was significantly higher than that in the OVX-CON rats ( Table 2) , but in the late metabolic balance, calcium absorption efficiency was similar among all OVX groups. Fecal calcium and calcium retention did not differ among all groups in either the early or late metabolic balances. However, OVX-SYN, OVX-GEN, and OVX-GEN + SYN groups had higher urinary calcium than * , **Statistical significance at P G 0.05 from sham and OVX-CON controls. ANOVA, analysis of variance, OVX-CON, ovariectomized rats control group; OVX-E 2 , ovariectomized rats receiving estradiol treatment; OVX-SYN, ovariectomized rats receiving Synergy treatment; OVX-GEN, ovariectomized rats receiving genistein; OVX-GEN + SYN, ovariectomized rats receiving both genistein and Synergy. did the OVX-E 2 rats in the early metabolic balance but not in the late metabolic balance, where levels were similar across all groups.
Calcium kinetics
Rats consuming both genistein and Synergy had significantly higher bone formation and resorption rates than did all other groups (Table 3 ). OVX-E 2 and OVX-GEN rats had significantly lower bone resorption rates than did the rats in the OVX-CON and OVX-GEN + SYN groups. The sham control rats had a trend (P = 0.07) for lower bone resorption rate compared with OVX-CON rats. Rats consuming only Synergy had significantly higher calcium absorption efficiency than did OVX-CON (41%) and OVX-GEN rats. OVX-GEN + SYN rats had significantly higher bone balance than the rats in the OVX-E 2 , OVX-GEN, and OVX-CON groups. There was also a trend (P = 0.08) of higher bone balance for OVX-SYN rats compared with OVX-CON rats.
pQCT measurements
The distal femur was more responsive to dietary treatment than was either the midshaft or proximal femur. At the distal femur, sham rats had significantly higher total bone mineral content (BMC) and volumetric BMD (vBMD) and trabecular BMD than did all OVX groups (Table 1) . Genistein consumption with Synergy resulted in a significant trend for higher trabecular BMD levels compared with nonconsumption (OVX-CON).
At the midshaft femur, sham rats had significantly higher total BMC than did the rats in the OVX-CON and OVX-GEN + SYN groups, as well as a trend (P = 0.09) for OVX-GEN rats ( Table 1) . OVX-E 2 and OVX-SYN rats had total BMC similar to that of the sham rats. The sham rats had significantly higher total BMD than did the OVX-CON and OVX-E 2 rats.
At the proximal femur, the sham rats had significantly higher total BMD than did the rats in all OVX groups.
SCFA analysis
OVX-SYN and OVX-GEN + SYN rats had significantly higher total SCFA concentration in cecal contents than did sham rats (Table 4 ). Rats consuming Synergy (OVX-SYN and OVX-GEN + SYN groups) also had significantly higher levels of propionate than did all other groups. OVX-SYN rats also had a significantly higher acetate concentration than did sham rats and higher acetate levels than did the rats in other OVX groups. There were no significant differences in isobutyrate, butyrate, and isovalerate concentrations between groups.
DISCUSSION
Research involving prebiotics and phytoestrogens has focused on bone and gut health, but there has also been great interest in their heart health benefits. 8, 28 A meta-analysis of 40 randomized controlled trials showed that soy protein and isoflavone supplementation lowered serum lipids in a dosedependent manner. 29 Inulin and FOS improved lipid profiles in animals at high doses, but clinical results have been mixed. 30 In addition to cardiovascular disease, postmenopausal women also have a higher risk of type 2 diabetes and insulin resistance. 18 Our study findings indicate that genistein may play a role in ameliorating metabolic syndrome in postmenopausal women. In our study, genistein supplementation lowered total cholesterol, whereas Synergy consumption had no benefit on lipid levels. We also observed that genistein consumption and E 2 injections aided in preventing the increase in weight usually associated with estrogen deficiency. This corresponds with our previous findings showing that E 2 25 and equol, 24 a soy isoflavone metabolite, inhibited ovariectomy-induced weight gain. In spontaneously hypertensive OVX rats and in Wistar control rats, genistein consumption for 4 weeks led to lower plasma lipid levels, increased HDL cholesterol levels, and reduced insulin resistance. 31 In rats and in humans, increases in BMD and BMC are related to the risk of fracture. Modest benefits of genistein to BMD and BMC, 32 as well as to the trabecular bone, 33 have been reported but without benefit to bone strength or trabecular microarchitecture. 34, 35 Clinical studies showed that genistein supplementation improved the bone health of early postmenopausal to midpostmenopausal (1-5 y after menopause) women (average age range, 50-55 y). Our study findings indicate that genistein aided in restoring total and trabecular vBMD at the distal femur to levels no different from the premenopausal state, but few other benefits to the bone were observed. Conflicting results in studies could be caused by differences in treatment duration, length of stabilization after ovariectomy, method of administration, and age at the start of treatment. Most studies have been conducted on young animal models (1-3 mo old) after receiving SC injections of genistein directly or shortly after menopause (1-4 wk) for short treatment duration (3-4 wk) and showed improvement in femoral bone properties. 36<38 Few studies in older animals have assessed the effect of genistein with longer treatment duration with mixed results. Picherit et al 39 observed no effect of genistein in 12-month-old Wistar rats after administering a daily oral gavage (10 Kg of genistein/g of body weight E 2 ) directly after ovariectomy for 3 months. Genistein supplementation provided only minimal benefits to bone microarchitecture after daily SC injections in 7-month-old Sprague-Dawley rats for 15 weeks. 33 Greater improvements in femoral BMC and BMD were observed in 9-month-old Wistar rats after administering genistein (1 and 10 mg/kg SC injections) 6 months after ovariectomy for 12 weeks. 32 Findings from our study, as well as previous works, suggest that, to have bone health effects in stable postmenopausal women, genistein levels need to be higher than doses readily obtained through dietary supplementation. In contrast to genistein, Synergy consumption improved calcium utilization as determined by the sensitive kinetic modeling approach. It has been proposed that prebiotics exert effects on bone health through improved mineral metabolism by increasing SCFA concentrations, which lowers intestine pH levels and causes higher mineral absorption. Suggestive of this hypothesis, Synergy consumption led to higher SCFA concentrations in the cecum, increased calcium absorption efficiency, and higher bone calcium balance as determined by calcium kinetics, which is consistent with previous findings. 4 Calcium kinetics also showed that rats consuming both genistein and Synergy had higher bone turnover and calcium balance than did the rats in other groups. However, rats consuming Synergy only had higher femoral strength than did the rats consuming both genistein and Synergy, suggesting that the interaction between genistein and Synergy needs to be further explored. Perhaps, an examination of this interaction in vitro will expose the modes of action on bone metabolism that accounts for the effects seen in vivo. Increased net calcium absorption efficiency with Synergy, when combined with genistein, was also observed early but not late in this study. Adaptation effects were also observed with sc-FOS. 36 Supplementation of Synergy with genistein resulted in higher circulating genistein than did consuming genistein alone. Similarly, sc-FOS modified the absorption and enterohepatic recirculation of soy isoflavones in rats. 37, 38 Higher circulating phytoestrogen levels due to prebiotic consumption could be the main contributor to synergistic effects of sc-FOS and isoflavones on femoral 21, 22 and lumbar BMD. 20 In our study, we did not observe the synergistic effects of Synergy (50%/50% mix of inulin and sc-FOS) and genistein on bone or heart health, which agrees with previous work examining inulin and isoflavones. 23 This suggests that potential synergy between prebiotics and phytoestrogens may depend on the chain length of oligosaccharides, that is, sc-FOS versus the long chains of inulin.
Limitations of our study include the multiple outcome comparisons that decrease our power to see individual effects. A longer duration of intervention through at least two remodeling cycles may have shown greater impact of treatment.
CONCLUSIONS
In summary, prebiotics but not dietary genistein influences bone health except for distal femur vBMD, whereas genistein shows more impact on heart health. A combination of a Denotes statistical significance at P G 0.05 from OVX-CON group. prebiotic and genistein does not manifest any extra health benefits. Dietary genistein may play a role in cardiovascular events associated with menopause because a 200 mg genistein/kg diet dose improved cholesterol profiles in the postmenopausal rat model. This dose correlates to a diet high in soy (ie, Asian/vegetarian diets). It can also be obtained through commercially available dietary supplements. The minimal effect on the bone observed in genistein supplementation in stable OVX rats indicates that genistein may be not beneficial for bone health in postmenopausal women in the middle or latter stages of menopause. Synergy, at 5% of the diet, increases calcium absorption but does not improve other bone health parameters. Further exploration on the effect of prebiotics on calcium metabolism and subsequent impact on bone properties is needed.
